Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Multicenter, Phase -IV Study to Assess the Safety of Fixed Dose Combination of Dapagliflozin and Saxagliptin in Indian Type 2 Diabetes Mellitus (T2D) Patients

NCT04445714 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT04445714
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04445714 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Multicenter, Phase -IV Study to Assess the Safety of Fixed Dose Combination of Dapagliflozin and Saxagliptin in Indian Type 2 Diabetes Mellitus (T2D) Patients
Lead sponsor
AstraZeneca
Phase
Phase 4
Overall status
Completed
Start date
April 7, 2021
Completion date
March 14, 2023
Enrollment
196 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

type 2 diabetes mellitus